{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:50:08Z","timestamp":1790607008131,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R01 AA021164"],"award-info":[{"award-number":["R01 AA021164"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R01 AA023192"],"award-info":[{"award-number":["R01 AA023192"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["VISN 4 Mental Illness Research, Education and Clinical Center"],"award-info":[{"award-number":["VISN 4 Mental Illness Research, Education and Clinical Center"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Studies of the efficacy of gabapentin for treating alcohol use disorder (AUD) have yielded mixed findings. The aims of our study were to estimate gabapentin's effects on six alcohol\u2010related outcomes, test potential moderators, examine publication bias and evaluate the quality of the studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Meta\u2010analysis of placebo\u2010controlled randomized controlled trials (RCTs). Using PubMed and ClinicalTrials.gov, we selected RCTs of gabapentin's effects on alcohol consumption or a biochemical correlate of it, excluding studies limited to other primary outcomes or that combined gabapentin with other medications. We assessed study quality and used a random\u2010effects model to analyze each outcome measure and the Egger regression test and funnel plots to assess publication bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified seven RCTs of gabapentin that met study criteria. The quality of the studies overall was good, and there was no evidence of publication bias. Four to seven studies contributed to the analysis of the six outcome measures. For all outcome measures the effect estimates were in a direction that favored gabapentin over placebo. However, only for percentage of heavy drinking days was there good evidence of a benefit (\n                      <jats:italic>g<\/jats:italic>\n                      \u00a0=\u00a0\u22120.64, 95% confidence interval\u00a0=\u00a0\u22121.22 to \u22120.06).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although gabapentin appears to be more efficacious than placebo in treating AUD, the only measure on which the analysis clearly favors the active medication is percentage of heavy drinking days. Additional studies are needed to define more clearly the role of gabapentin in AUD treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.14655","type":"journal-article","created":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T09:59:23Z","timestamp":1557568763000},"page":"1547-1555","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["A meta\u2010analysis of the efficacy of gabapentin for treating alcohol use disorder"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1018-0450","authenticated-orcid":false,"given":"Henry R.","family":"Kranzler","sequence":"first","affiliation":[{"name":"Department of Psychiatry University of Pennsylvania Perelman School of Medicine  Philadelphia PA USA"},{"name":"Mental Illness Research, Education and Clinical Center of the Veterans Integrated Service Network 4 Crescenz Veterans Affairs Medical Center  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Feinn","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Frank H. Netter School of Medicine at Quinnipiac University  North Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of Pennsylvania Perelman School of Medicine  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily E.","family":"Hartwell","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of Pennsylvania Perelman School of Medicine  Philadelphia PA USA"},{"name":"Mental Illness Research, Education and Clinical Center of the Veterans Integrated Service Network 4 Crescenz Veterans Affairs Medical Center  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,5]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Food and Drug Administration (FDA).2017.Neurontin Prescribing Information. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020235s064_020882s047_021129s046lbl.pdf(accessed 16\u00a0December 2018)."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2005.11.003"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.01.013"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015585849"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1108"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2018.09.002"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.13917"},{"key":"e_1_2_7_9_1","unstructured":"MarianiJJ.Gabapentin for abstinence initiation in alcohol dependence.ClinicalTrialsgov. Published2018. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01141049(accessed 27\u00a0October 2018) (Archived athttp:\/\/www.webcitation.org\/78T8PthVNon 18 May 2019)"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.10.008"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2006.00299.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2016.1163315"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13324"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1704633"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_7_16_1","unstructured":"SidhuS. S.Treatment for alcohol dependence with gabapentin. ClinicalTrialsgov. Published2018. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02771925(accessed 27\u00a0October 2018). (Archived at:http:\/\/www.webcitation.org\/78l6sPZW2on 30 May 2019)"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3102\/10769986006002107"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2008.00706.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.11950"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADT.0b013e31812e6a3c"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.8313"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1996.tb01036.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.1750101"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.12411"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP203166"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10101436"},{"key":"e_1_2_7_29_1","article-title":"Gabapentin for chronic neuropathic pain in adults","author":"Wiffen P. J.","year":"2017","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.14655","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.14655","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.14655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T12:10:41Z","timestamp":1781179841000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.14655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,5]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1111\/add.14655"],"URL":"https:\/\/doi.org\/10.1111\/add.14655","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,5]]},"assertion":[{"value":"2019-01-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}